

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q90950

Rena NISHIZAWA, et al.

Appln. No.: Based on PCT/JP04/005493

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: October 18, 2005

Examiner: Unknown

For: SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith via CD-ROM, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after


INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP04/005493
Attorney Docket No.: Q90950

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/005493 dated August 3, 2004), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Mark Boland
Registration No. 32,197

Date: October 18, 2005

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				Complete if Known 10/553596	
				Application Number	Based on PCT/JP04/005493
				Confirmation Number	Unknown
				Filing Date	October 18, 2005
				First Named Inventor	Rena NISHIZAWA
				Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	Q90950
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 2003/0187023	A1	10-02-2003	Keiji Kubo, et al.
		US 6,291,469	B1	09-18-2001	Matthew J. Fisher, et al.
		US 2002/018124	A1	12-19-2002	Mark Nelson, et al.
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	03/020721	A1	03-13-2003	NOVARTIS AG	
		JP	49-72332	A	07-12-1974	SANKYO CO., LTD.	
		JP	49-13184	A	02-05-1974	SANKYO CO., LTD	
		JP	4-18092	A	01-22-1992	YAMANOUCHI PHARMACEUTICAL CO., LTD.	
		WO	95/01358	A1	01-12-1995	BAYER AKTIENGALLSCHAFT	Abstract
		JP	2002-348288	A	12-04-2002	ONO PHARMACEUTICAL CO., LTD.	
		WO	03/057698	A2	07-17-2003	ACADIA PHARMACEUTICALS, INC.	
		WO	02/074770	A1	09-26-2002	ONO PHARMACEUTICAL CO., LTD.	Abstract
		WO	97/11940	A1	04-03-1997	ELI LILLY AND COMPANY	
		WO	98/25605	A1	06-18-1998	MERCK & CO., INC.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		International Search Report for PCT/JP04/005493	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.